Research programme: prostaglandin E synthase inhibitors - OrexoAlternative Names: OX-MPI
Latest Information Update: 08 Aug 2014
At a glance
- Originator Biolipox
- Developer Biolipox; Boehringer Ingelheim
- Mechanism of Action Prostaglandin-E synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation; Pain; Rheumatoid arthritis
- Discontinued Fever; Osteoarthritis